Egypt Multiple Myeloma Research Review Issue 4

In this issue:
  -  Venetoclax for nontrial patients with MM
  -  Teclistamab for relapsed/ refractory MM
  -  COVID-19 outcomes in MM patients treated with novel drugs
  -  Venetoclax + carfilzomibdexamethasone in relapsed/refractory MM
  -  Lenalidomide maintenance duration and salvage regimen outcomes in MM
  -  Antimyeloma treatment affects response to COVID-19 vaccines
  -  Maintenance daratumumab after VTd ±daratumumab and autologous SCT in newly diagnosed MM
  -  Serum BCMA level predicts time to smouldering MM progression
  -  Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 for MM
  -  Predicting survival and optimising treatment in MM using machine-learning

Download PDF Subscribe